Results 111 to 120 of about 2,155 (206)

Long-Term Control of Retinal Thickness Variability and Vision Following the 0.19 mg Fluocinolone Acetonide Implant. [PDF]

J Vitreoretin Dis, 2023
Sheth VS, Singer M, MacCumber M, Cutino A, Kasper J, Coughlin BA, Riemann CD.   +6 more
europepmc   +1 more source

Gestione dell'edema maculare diabetico [PDF]

, 2011
Gestione dell'edema maculare diabetico, nuove ...
CAPUTO, SILVESTRO
core  

Letter to the Editor Regarding the “Effectiveness of 190 μg Fluocinolone Acetonide and 700 μg Dexamethasone Intravitreal Implants in Diabetic Macular Edema Using the Area-Under-the-Curve Method: The Constant Analysis” Article [Letter]

Clinical Ophthalmology, 2020
Kasserine Taylor,1 Michael W Stewart2 1Department of Ophthalmology, Mayo Clinic Florida, Jacksonville, FL, USA; 2Cornell University, Ithaca, NY, USACorrespondence: Michael W StewartDepartment of Ophthalmology, Mayo Clinic Florida, 4500 San Pablo Road ...
Taylor K, Stewart MW
doaj  

Preserflo Microshunt Surgery for Ocular Hypertension following Intravitreal Fluocinolone Acetonide Implant Removal: A Case Report. [PDF]

Case Rep Ophthalmol, 2022
Rezkallah A, Loria O, Mathis T, Chacun S, Denis P, Kodjikian L.   +5 more
europepmc   +1 more source

Clinical efficacy and safety of intravitreal fluocinolone acetonide implant for the treatment of chronic diabetic macular oedema: five-year real-world results. [PDF]

Eye (Lond), 2023
Dobler E, Mohammed BR, Chavan R, Lip PL, Mitra A, Mushtaq B.   +5 more
europepmc   +1 more source

A novel intravitreal fluocinolone acetonide implant (Iluvien®) in the treatment of patients with chronic diabetic macular edema that is insufficiently responsive to other medical treatment options: a case series

Clinical Ophthalmology, 2015
Vera K Schmit-Eilenberger Augenklinik Städtisches Klinikum, Karlsruhe, Baden-Württemberg, Germany Background: Iluvien® is a novel, nonbiodegradable, sustained-release drug delivery system (0.2 µg/d fluocinolone acetonide [FAc ...
Schmit-Eilenberger VK
doaj  

Challenging Clinical Cases – A Walk Through Supplemental Therapy with Intravitreal Ranibizumab Therapy Following Treatment of Diabetic Macular Edema with the 0.19 mg Fluocinolone Acetonide Implant (ILUVIEN®)

International Medical Case Reports Journal, 2020
Bernardete Pessoa,1,2 João Melo-Beirão,1,2 Angelina Meireles,1,2 Pedro Menéres1,2 1Ophtalmology Department, Centro Hospitalar e Universitário do Porto, Porto, Portugal; 2Unit for Multidisciplinary Research in Biomedicine ...
Pessoa B, Melo-Beirão J, Meireles A, Menéres P   +3 more
doaj  

Fluocinolone acetonide 0.2 μg/day intravitreal implant in non-infectious uveitis affecting the posterior segment: EU expert user panel consensus-based clinical recommendations. [PDF]

Background: Non-infectious uveitis affecting the posterior segment of the eye (NIU-PS) is an inflammatory disease, which can significantly impair visual acuity if not adequately treated.
Bodaghi Bahram, Burke Tomás, Devonport Helen, Heinz Carsten, Kodjikian Laurent, Llorenç Víctor, Miserocchi Elisabetta, Nogueira Vanda, Pavesio Carlos, Pleyer Uwe   +9 more
core   +1 more source

Cytomegalovirus endotheliitis following fluocinolone acetonide (Retisert) implant [PDF]

Eye, 2009
J L Sims, S P Chee
openaire   +1 more source

Intravitreal Fluocinolone Acetonide Implant (FAc, 0.19 mg, ILUVIEN®) in the Treatment of Patients with Recurrent Cystoid Macular Edema After Pars Plana Vitrectomy. [PDF]

Ophthalmol Ther, 2023
Lima-Fontes M, Leuzinger-Dias M, Barros-Pereira R, Fernandes V, Falcão M, Falcão-Reis F, Rocha-Sousa A, Alves-Faria P.   +7 more
europepmc   +1 more source